Kathmere Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Kathmere Capital Management's VRTX Position: Q2 2026 in Review
Kathmere Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 8.2% in Q2 2026, buying an estimated $17.7K and bringing the position to 529 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #558.
Kathmere Capital Management first reported a position in VRTX in Q4 2020 and has held it in 5 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Kathmere Capital Management held 529 shares of Vertex Pharmaceuticals worth $263K as of Q2 2026.
- Kathmere Capital Management bought 40 Vertex Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
- Vertex Pharmaceuticals made up 0.01% of Kathmere Capital Management's portfolio in Q2 2026, its #558 holding.
- Kathmere Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 5 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.